Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
Holding LUNG?
Track your performance easily
LUNG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.46 - $14.84
Previous Close$6
Volume179.32K
Average Volume (3M)241.49K
Market Cap
$236.93M
Enterprise Value$184.96M
Total Cash (Recent Filing)$107.78M
Total Debt (Recent Filing)$55.81M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Feb 19, 2025EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.47
Shares Outstanding39,487,879
10 Day Avg. Volume198,657
30 Day Avg. Volume241,485
Standard Deviation0.18
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.52
Price to Sales (P/S)3.16
Price to Cash Flow (P/CF)-8.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit3.64
Enterprise Value/Ebitda-3.69
Forecast
1Y Price Target
$13.50Price Target Upside117.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Pulmonx News
PremiumCompany Announcements
Pulmonx Corporation Reports Solid Revenue Growth in Q3 2024
Bulls Say, Bears Say
Bulls Say
Clinical Progress89% of CV-converted patients achieved a treated lobar volume reduction (TLVR) following the Zephyr implant.
Growth PotentialPulmonx is among the top 20 projected fastest growing medical device companies in the U.S., yet trades at less than half of this group's average forward EV/Revenue multiple.
Market ExpansionAeriseal increases the total addressable market (TAM) for Zephyr by approximately 20%.
Bears Say
Leadership UncertaintyThe unforeseen retirement of long-time CEO Glen French and the resignation of CFO Derrick Sung overshadowed the refocused strategy that reaccelerated 2023 growth to 28% from 11% in 2022.
Management ChangesThe unforeseen retirement of long-time CEO Glen French and the resignation of CFO Derrick Sung overshadowed the refocused strategy that reaccelerated 2023 growth.
Stock PerformanceThere is inherent uncertainty that comes with any management change, but the stock's 50% decline since announcing the CEO change does not accurately reflect Pulmonx's underlying fundamentals.
---
Ownership Overview
10.87% Insiders
35.83% Mutual Funds
30.18% Other Institutional Investors
7.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $5.46 and its highest was $14.84 in the past 12 months.
What is Pulmonx’s market cap?
Currently, no data Available
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Feb 19, 2025 which is in 90 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Oct 30, 2024. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.449 by $0.089.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -$0.45.
How many shares outstanding does Pulmonx have?
Pulmonx has 39,487,880 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.449. Following the earnings report the stock price went down -7.953%.
Which hedge fund is a major shareholder of Pulmonx?
Among the largest hedge funds holding Pulmonx’s share is PRIMECAP Management Co. It holds Pulmonx’s shares valued at 47M.
---
Pulmonx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (117.74% Upside)
$13.50 (117.74% Upside)
Blogger Sentiment
Bullish
LUNG Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 33.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.70%
12-Months-Change
Fundamentals
Return on Equity
-51.99%
Trailing 12-Months
Asset Growth
-9.52%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
---
LUNG Earnings Call
Q3 2024
0:00 / 0:00
---
LUNG Stock 12 Month Forecast
Average Price Target
$13.50
▲(117.74% Upside)
Technical Analysis
Best Analysts Covering LUNG
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-19.40%
reiterated a buy rating 7 months ago
Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -19.40% per trade.
---